The OHSN-REB reviews each participant Informed Consent Form (ICF) to
ensure that the information that is being presented to participants
is clear and accurate.
All consent forms must be submitted with your initial REB
application.
Please ensure information in the ICF is consistent with the research
protocol and the REB application form. The OHSN-REB specifically
reviews these documents for consistency.
All ICFs must be approved by the OHSN-REB
before
being given to potential research participants.
Once signed, the original Informed Consent Form must be kept
securely with the study essential documents. A copy of the signed
document must be provided to the study participant.
Any changes required to an approved document, must be submitted as
an amendment and approved by the OHSN-REB before use.
Research participants may be required to sign the revised Informed
Consent Form. If the research participant has completed his/her
participation in the study, the investigator must inform him/her
about any new information which may affect them, e.g., safety
information. However, if there is no possible impact to them (e.g.
visit schedule change or drug dosing change for those still on
therapy, etc.) there is no need to re-contact for re-consent.
OHSN-REB Templates
|
Please follow the instruction page at the beginning of each
template and ensure the instruction page is removed prior to
submission to the OHSN-REB.
|
Template Language |
Version Date |
Informed Consent Form (ICF) Checklist |
|
|
All ICF templates have been designed to meet current regulatory
and ethical standards.
|
English only
|
December 7, 2017 |
The ICF checklist identifies the regulations, guidelines and
policies that require the language in the ICF templates. The
checklist is meant to be used as a guide to ensure all
applicable elements are present in the consent form.
|
|
|
Main Clinical Trial/Study Informed Consent Form |
|
|
To be used for studies that are above minimal risk. |
|
|
-
Main Clinical Trial/Study Informed Consent Form Template
|
English
/
French
|
February 10, 2022 |
-
Summary of revisions to the main clinical trial/study
consent template
|
English only
|
February 10, 2022 |
Minimal Risk Informed Consent Form |
|
|
To be used for minimal risk studies only. |
|
|
- Minimal risk Informed Consent Form Template
|
English
/
French
|
February 10, 2022 |
-
Summary of revisions to the minimal risk consent template
|
English only
|
February 10, 2022 |
Optional Informed Consent Form |
|
|
To be used as a supplement to the main study consent form when
there is an optional component for the study (e.g.: optional
biomarker research, optional genetic research, optional
bio-banking, etc.).
|
|
|
- Optional Informed Consent Form Template
|
English
/
French
|
February 10, 2022 |
-
Summary of revisions to the optional informed consent
template
|
English only
|
February 10, 2022 |
Pregnant Partner Release of Information Informed Consent Form
|
|
|
Not required at the time of initial ethics submission. To be
created when the pregnancy event occurs, and only if the
ethics application and main participant ICF indicated that the
investigator planned to collect information from the partner
should she become pregnant.
The pregnant partner ICF must be submitted with a Main
Reportable Event Form and Pregnant Partner Event section form;
see the 'Forms' tab of the OHSN-REB website.
Note: If a sponsor requires the pregnant partner consent form
to be submitted at the time of initial ethics submission, it
may be uploaded into the application for review and approval.
|
|
|
-
Pregnant Partner Release of Information Informed Consent
Form Template
|
English
/
French
|
April 14, 2021 |
-
Summary of revisions to the pregnant partner informed
consent template
|
English only
|
April 14, 2021 |
Update Informed Consent Form |
|
|
To be used for participant re-consent purposes only. |
|
|
- Update Informed Consent Form Template
|
English
/
French
|
December 7, 2017 |
-
Guidance for Providing New Information to Study Participants
|
English only
|
December 7, 2017 |
Main Informed Consent Form for
Oncology Studies
|
|
|
To be used for oncology studies that are submitted for local
OHSN-REB ethics approval.
|
|
|
-
Main Informed Consent form for local oncology studies
Template
|
English
/ French
|
April 14, 2021 |
-
Summary of revisions to the main consent for local oncology
studies template
|
English only
|
April 14, 2021 |
Verbal Consent (minimal risk studies only) |
|
|
To be used for minimal risk studies only, when the participant
will verbally agree to participate in the research (written
signature will not be collected).
|
|
|
- Guidance on Verbal Consent Process
|
English only |
Coming soon |
|
English
/
French
|
December 3, 2020 |
|
English
/
French
|
July 15, 2021 |
Implied Consent (minimal risk studies only) |
|
|
To be used for minimal risk studies only. Implied consent occurs
through the actions or conduct of the participant rather than
direct communication through words. For example, when the
participant will indicate that they knowingly agree to
participate in the research by completing a research activity,
most commonly a one-time survey/questionnaire (written or verbal
consent will not be obtained).
|
|
|
- Guidance on Implied Consent Process
|
English only
|
Coming soon |
|
English
/
French
|
December 3, 2020 |
Virtual/Remote Recruitment and Consent |
|
|
Participants may be recruited and/or consented remotely when
in-person recruitment and/or consent is not feasible, provided
the remote methods adhere to ethical principles and privacy
protections.
|
|
|
- Virtual Guidelines for Studies Requiring Written Consent
|
English only
|
July 15, 2021 |
-
Request for Use of Alternative Virtual Platforms at TOH
|
English only
|
July 25, 2024 |
- Request for Use of Third-Party Technologies at TOH and UOHI
|
English only
|
February 10, 2022 |
Secure Methods of Document Transfer:
|
|
|
|
English only
|
May 2021 |
-
Instructions for Use of Microsoft 365 SharePoint and
OneDrive
|
English only
|
November 25, 2020 |
- Instructions for Use of Mail
|
English only
|
July 15, 2021 |
- Instructions for Use of Fax
|
English only
|
July 15, 2021 |
-
Instructions for Use of Photograph to Document Written
Consent
|
English only
|
Coming soon |
-
Instructions for Use of MS Teams Chat to Send and Receive
Documents
|
English only
|
July 15, 2021 |
Note: For guidance on use of email with patients, please see the
'Email Process and Templates' section below.
|
|
|
Electronic Signature Platforms approved for Use:
NOT Health
Canada or FDA Compliant:
|
|
|
- Guidance for Use of DocuSign
|
English only
|
Coming soon |
|
English only
|
Coming soon |
Health Canada or FDA Compliant:
|
|
|
-
Guidance for Use of TOH Methods Centre Electronic Data
Capture System (EDCS)
|
English only
|
Coming soon |
Audio and/or Video Recording:
|
|
|
-
Guidelines for Use of Audio and/or Video Recording of
Participants
|
English only
|
July 15, 2021 |
-
Instructions for Audio and Video Recording in Microsoft
Teams
|
English only
|
July 15, 2021 |
- Instructions for Transcription in Microsoft Teams
|
English only
|
July 15, 2021 |
Email Process and Templates |
|
|
Process for contacting patient participants via email:
|
|
|
- OHSN-REB Guidance for Use of Email in Clinical Research
|
English only
|
October 20, 2023 |
- Use of Patient Email in Clinical Research – Researcher FAQs
|
English only
|
October 20, 2023 |
-
Guidance for Obtaining Participant Consent Using the
"Research Participant Consent to Communicate by Email" Form
|
English only
|
October 20, 2023 |
-
Consent Form: Research Participant Consent to Communicate by
Email
|
English
/
French
|
November 20, 2020 |
Email Templates:
|
|
|
- Email Template - Staff Recruitment Email
|
English only
|
September 15, 2023 |
- Email Template - Patient Recruitment Email
|
English only
|
October 5, 2023 |
- Email Template - Reminder Recruitment Email
|
English
/
French
|
December 3, 2020 |
- Email Template - Appointment Reminder
|
English
/
French
|
December 3, 2020 |
- Email Template - Survey/Questionnaire Reminder
|
English
/
French
|
December 3, 2020 |
-
Email Template - Sending ICF to Potential Participant
|
English /
French
|
July 15, 2021 |
Onsite In-Person Impartial Witness Consenting Process During the
COVID-19 Pandemic
|
|
|
To be utilized onsite during an in-person consenting process
when there is a potential risk of COVID-19 therefore a signature
from the participant is not able to be obtained. For example,
potential participant in isolation for COVID-19 and not able to
share pen/paper.
|
|
|
-
Guidance for In-Person Consenting Process with the use of an
Impartial Witness
|
English only
|
Coming soon |
-
In-person Consenting with Impartial Witness Process
Checklist
|
English only
|
October 15, 2020 |
- Impartial Witness Addendum to Consent Signature Page
|
English
/ French
|
October 15, 2020 |
Other: |
|
|
|
English
/
French
|
December 13, 2023 |
- Recruitment In-class Script
|
English
/
French
|
December 7, 2017 |
|
English /
French
|
July 15, 2021 |
|
English
/
French
|
December 7, 2017 |
|
English
/
French
|
December 7, 2017 |
- Guidance Research with Minors
|
English only
|
December 7, 2017 |